Literature DB >> 25342742

Activation of glioma cells generates immune tolerant NKT cells.

Bo Tang1, Wei Wu2, Xiaowei Wei3, Yang Li1, Gang Ren3, Wenhai Fan4.   

Abstract

Therapeutic outcomes of glioma are currently not encouraging. Tumor tolerance plays an important role in the pathogenesis of glioma. It is reported that micro RNAs (miR) are associated with tumor development. This study aims to investigate the role of miR-92a in the development of tolerant natural killer T (NKT) cells. In this study, U87 cells (a human glioma cell line) and primary glioma cells were prepared. The assessment of miR-92a was performed by real time RT-PCR. The expression of interleukin (IL)-10 and IL-6 in NKT cells was evaluated by flow cytometry. Results showed that abundant IL-6(+) IL-10(+) NKT cells were detected in glioma tissue. Cultures of glioma cells and NKT cells induced the expression of IL-6 and IL-10 in NKT cells. Glioma cells expressed miR-92a; the latter played a critical role in the induction of IL-6 and IL-10 expression in NKT cells. The expression of the antitumor molecules, including perforin, Fas ligand, and interferon-γ, was significantly attenuated compared with control NKT cells. The IL-6(+) IL-10(+) NKT cells showed less capability in the induction of apoptosis in glioma cells, but showed the immune suppressor functions on CD8(+) T cell activities. We conclude that glioma-derived miR-92a induces IL-6(+) IL-10(+) NKT cells; this fraction of NKT cells can suppress cytotoxic CD8(+) T cells.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Cellular Immune Response; Glioblastoma; Lymphocyte; RNA; Tolerance

Mesh:

Substances:

Year:  2014        PMID: 25342742      PMCID: PMC4263866          DOI: 10.1074/jbc.M114.614503

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset.

Authors:  Duygu Sag; Petra Krause; Catherine C Hedrick; Mitchell Kronenberg; Gerhard Wingender
Journal:  J Clin Invest       Date:  2014-07-25       Impact factor: 14.808

Review 2.  miR-92a family and their target genes in tumorigenesis and metastasis.

Authors:  Molin Li; Xingfang Guan; Yuqiang Sun; Jun Mi; Xiaohong Shu; Fang Liu; Chuangang Li
Journal:  Exp Cell Res       Date:  2014-01-04       Impact factor: 3.905

3.  Generation and identification of tumor-evoked regulatory B cells.

Authors:  Arya Biragyn; Catalina Lee-Chang; Monica Bodogai
Journal:  Methods Mol Biol       Date:  2014

4.  Natural killer T cells: drivers or passengers in preventing human disease?

Authors:  Stuart P Berzins; David S Ritchie
Journal:  Nat Rev Immunol       Date:  2014-08-08       Impact factor: 53.106

5.  miR-27a regulates inflammatory response of macrophages by targeting IL-10.

Authors:  Na Xie; Huachun Cui; Sami Banerjee; Zheng Tan; Reinaldo Salomao; Mingui Fu; Edward Abraham; Victor J Thannickal; Gang Liu
Journal:  J Immunol       Date:  2014-05-16       Impact factor: 5.422

6.  MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.

Authors:  Lin Wang; Zhu-Mei Shi; Cheng-Fei Jiang; Xue Liu; Qiu-Dan Chen; Xu Qian; Dong-Mei Li; Xin Ge; Xie-Feng Wang; Ling-Zhi Liu; Yong-Ping You; Ning Liu; Bing-Hua Jiang
Journal:  Oncotarget       Date:  2014-07-30

7.  Glioma-derived ADAM10 induces regulatory B cells to suppress CD8+ T cells.

Authors:  Zhuo-peng Ye; Hai-yong He; Hui Wang; Wen-sheng Li; Lun Luo; Zhen-chao Huang; Ying Guo
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

8.  The miR-17 ∼ 92a cluster of microRNAs is required for the fitness of Foxp3+ regulatory T cells.

Authors:  Jarrod P J Skinner; Ashleigh A Keown; Mark M W Chong
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

9.  Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, β-Catenin, CBP, and STAT3.

Authors:  Ronghong Li; Xiang Li; Shangwei Ning; Jingrun Ye; Lei Han; Chunsheng Kang; Xia Li
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

10.  Competing targets of microRNA-608 affect anxiety and hypertension.

Authors:  Geula Hanin; Shani Shenhar-Tsarfaty; Nadav Yayon; Yin Hoe Yau; Yau Yin Hoe; Estelle R Bennett; Ella H Sklan; Dabeeru C Rao; Tuomo Rankinen; Claude Bouchard; Susana Geifman-Shochat; Sagiv Shifman; David S Greenberg; Hermona Soreq
Journal:  Hum Mol Genet       Date:  2014-04-09       Impact factor: 6.150

View more
  18 in total

Review 1.  MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment.

Authors:  F J Kohlhapp; A K Mitra; E Lengyel; M E Peter
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

Review 2.  Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment.

Authors:  Zijie Xu; Yi Chen; Ling Ma; Yizhang Chen; Jingya Liu; Yuchen Guo; Ting Yu; Lianghui Zhang; Lingjun Zhu; Yongqian Shu
Journal:  Mol Ther       Date:  2022-04-09       Impact factor: 12.910

Review 3.  Cancer-derived exosomic microRNAs shape the immune system within the tumor microenvironment: State of the art.

Authors:  Francesca Fanini; Muller Fabbri
Journal:  Semin Cell Dev Biol       Date:  2016-12-09       Impact factor: 7.727

Review 4.  Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.

Authors:  Wanli Yu; Sai Liang; Chunzhi Zhang
Journal:  Neuromolecular Med       Date:  2018-09-04       Impact factor: 3.843

Review 5.  Essential role of miRNAs in orchestrating the biology of the tumor microenvironment.

Authors:  Jamie N Frediani; Muller Fabbri
Journal:  Mol Cancer       Date:  2016-05-26       Impact factor: 27.401

6.  Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Claudia Mattei; Flora Vitale; Francesco Marampon; Alessandro Colapietro; Giulia Rossi; Luca Ventura; Antonella Vetuschi; Ernesto Di Cesare; Judith A Fox; Claudio Festuccia
Journal:  Oncotarget       Date:  2017-05-02

7.  TLR9-ERK-mTOR signaling is critical for autophagic cell death induced by CpG oligodeoxynucleotide 107 combined with irradiation in glioma cells.

Authors:  Xiaoli Li; Yanyan Cen; Yongqing Cai; Tao Liu; Huan Liu; Guanqun Cao; Dan Liu; Bin Li; Wei Peng; Jintao Zou; Xueli Pang; Jiang Zheng; Hong Zhou
Journal:  Sci Rep       Date:  2016-06-02       Impact factor: 4.379

Review 8.  Immunological Evasion in Glioblastoma.

Authors:  Roxana Magaña-Maldonado; Elda Georgina Chávez-Cortez; Nora Karen Olascoaga-Arellano; Mariana López-Mejía; Fernando Manuel Maldonado-Leal; Julio Sotelo; Benjamín Pineda
Journal:  Biomed Res Int       Date:  2016-05-15       Impact factor: 3.411

Review 9.  Effect of exosomal miRNA on cancer biology and clinical applications.

Authors:  Zhenqiang Sun; Ke Shi; Shuaixi Yang; Jinbo Liu; Quanbo Zhou; Guixian Wang; Junmin Song; Zhen Li; Zhiyong Zhang; Weitang Yuan
Journal:  Mol Cancer       Date:  2018-10-11       Impact factor: 27.401

10.  Advances in NKT cell Immunotherapy for Glioblastoma.

Authors:  Kalyani Pyaram; Viveka Nand Yadav
Journal:  J Cancer Sci Ther       Date:  2018-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.